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LETTERS TO EDITOR 
in life and beliefs should be considered at par 
with the functional variables. Thus how a patient 
judges the outcome and how the outcomes 
influences the health related quality of life is as 
important as clinician's judgement of prognosis. 
Hence considering a high prevalence 
(25%) of depression amongst the cancer patients 
we feel the presence of a psychiatrist, 
psychoanalyst alongwith the surgeon to 
completely evaluate the patient preoperatively. 
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CATATONIA : NEED FOR CLARIFICATION 
Sir, 
Payee et al.(1999) have confirmed 
contemporary opinion that lorazepam and 
electroconvulsive therapy are effective 
treatments for the catatonic syndrome 
irrespective of the etiology of the syndrome 
(Petrides & Fink, 1999). Two issues in their paper 
however beg clarification : 
1. At several places in the abstract and text, the 
authors aver that the duration of catatonia did 
not predict outcome with lorazepam; however, 
their table shows that the greater duration of 
pretreatment catatonia in lorazepam 
nonresponders (as compared with responders) 
was statistically significant. Which conclusion is 
correct? 
2. The authors do not discuss their patients' 
tolerance of lorazepam, the duration of 
lorazepam therapy specifically in treatment 
responders, and the experience of withdrawal 
of lorazepam after successful as well as 
unsuccessful therapy. These are important 
issues as high dose benzodiazepines are not 
always well tolerated, and as these drugs often 
occasion unpleasant withdrawal symptoms at the 
time of discontinuation. 
The authors' response to these issues 
would be helpful. 
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REPLY 
Sir, 
I am grateful to Dr. Chittaranjan Andrade 
for pointing out the error in Table-2 of our article 
titled "Catatonic Syndrome : Treatment 
Response to Lorazepam". Under duration of 
catatonia the mean rank score of responders 
should read as 22.85 and not as 12.85. The 
duration of catatonia was not found to be a 
significant predictor. 
Patients irciudsd under the study were 
subjected to a detailed clinical examination and 
appropriate investigations to rule out organicity. 
Majority of patients (n=16) responded to 
385 LETTERS TO EDITOR 
lorazepam by the end of second day of treatment. 
Five more patients could be declared as 
responders by the end of fourth day of treatment. 
Throughout the study period no adverse side 
effects were documented. No unpleasant 
withdrawal symptoms were reported following the 
termination of lorazepam. A large sample size 
needs to be studied to confirm these observations. 
R.CHANDRASEKARAN, Professor and Head, Department 
of Psychiatry, JIPMER, Pondicherry 
RE-EMERGENCE OF POSITIVE SYMPTOMS 
OF SCHIZOPHRENIA DURING THE COURSE 
OF TREATMENT WITH RISPERIDONE 
Sir, 
We would like to respond to the article titled 
"Re-emergence of positive symptoms of 
schizophrenia during the course of treatment with 
risperidone" (Bajaj et al.), that was published in 
the Indian Journal of Psychiatry, Vol.41/No.2/April, 
1999. It was quite interesting to note that these 
authors had observed a re-emergence of positive 
symptoms in 7 patients, out of 30 patients of 
schizophrenia treated with risperidone. We would 
like to present a brief report of a similar 
phenomenon observed in one schizophrenic 
patient undergoing treatment in the Dept. of 
Psychiatry, JIPMER Hospital, Pondicherry. 
Mr.X, a 28-yr. old unmarried male was 
hospitalized in August,1999 with an ICD-10 
diagnosis of residual schizophrenia. His illness 
had, by then, run a chronic unremitting course 
for three years, with a definite progression from 
an initial brief phase characterised by overt 
positive symptoms to the second and chronic 
stage, comprising all the typical negative 
symptoms such as avolition, apathy, social 
withdrawal, anhedonia, blunted affect and a 
gross reduction in speech output. A detailed 
cross-sectional evaluation soon after admission 
did not reveal any disorder of form of thought, 
delusions, thought-alienation phenomena or 
perceptual disturbances. Patient's baseline 
BPRS score was 24. Baseline PANSS profile was 
as follows : Positive syndrome score=11, 
negative syndrome score=46, general 
psychopathology score=39. Risperidone was 
initiated at a dose of 2 mg/day and gradually 
incraesed to a total of 8 mg/day in 2 divided 
doses. After 2 weeks of treatment with 8 mg of 
risperidone, interesting changes were observed 
in the patient's clinical profile and his scores on 
BPRS and PANSS. Total BPRS score had 
increased to 26, while the PANSS scores were 
as follows : Positive syndrome score=27, 
negative syndrome score=27, general 
psychopathology score=39. These rating scale 
scores correlated with clinically observed 
worsening of positive symptoms, especially 
conceptual disorganization and grandiosity and 
improvement in negative symptoms. 
This unusual and unexpected observation 
leads us to speculate on the rather unique 
receptor binding properties of risperidone 
(5HT2+D2 receptor antagonism), the relationship 
between the roles of serotonin and dopamine in 
schizophrenia and also the possibility of this 
phenomenon being essentially due to an 
idiosyncratic neurochemical profile in this 
particular patient. 5HT2 antagonists have been 
shown to have an antipsychotic effect, 
particularly on the negative symptom cluster 
(Bleich et a!.,1988). Research has also shown 
that risperidone is effective against both the 
positive and the negative symptoms of 
schizophrenia (Marder & Meibach,1994). 
Agarwal et al.(1998) had investigated the 
response of Indian schizophrenic patients to 
risperidone and observed a reduction in score 
in both the positive syndrome scale and the 
negative syndrome scale of PANSS. Based on 
the available literature, it is possible to explain 
the beneficial effect that risperidone has had on 
the negative symptoms of our patient. But, the 
apparent re-emergence/worsening of positive 
symptoms during treatment with risperidone is 
a strange phenomenon that seems to have no 
concrete explanation as yet. Bajaj et al.(1999) 
nave suggested that risperidone's 
antiserotonergic activity may possibly potentiate 
dopamine release at the mesolimbic region, 
counteracting the primary anti-psychotic activity, 
resulting in a re-emergence of positive 
symptoms. This is quite a plausible and 
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